Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag

Vaccine

Volumn 27, Issue 42, 2009, Pages 5735-5739

  de Goede, Anna L ^a   Boers, Patrick H M ^a   Dekker, Lennard J M ^a   Osterhaus, Albert D M E ^a   Gruters, Rob A ^a   Rimmelzwaan, Guus F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

HIV 1; Influenza; Viral vector

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; PROTEIN P17; RFLU P17 VIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS SIALIDASE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VIVO STUDY; INFLUENZA VIRUS A; LIQUID CHROMATOGRAPHY; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY; VIRUS RECOMBINANT; WESTERN BLOTTING;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; DOGS; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; INFLUENZA A VIRUS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; TANDEM MASS SPECTROMETRY;

EID: 69749120458     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.032     Document Type: Article

References (26)

1. Autran B., Debre P., Walker B., and Katlama C. Therapeutic vaccines against HIV need international partnerships. Nat Rev Immunol 3 6 (2003) 503-508
2. Letvin N.L. Correlates of immune protection and the development of a human immunodeficiency virus vaccine. Immunity 27 3 (2007) 366-369
3. Rimmelzwaan G.F., Nieuwkoop N.J., de Mutsert G., Boon A.C., Kuiken T., Fouchier R.A., et al. Attachment of infectious influenza A viruses of various subtypes to live mammalian and avian cells as measured by flow cytometry. Virus Res 129 2 (2007) 175-181
4. De Wit E., Spronken M.I., Bestebroer T.M., Rimmelzwaan G.F., Osterhaus A.D., and Fouchier R.A. Efficient generation and growth of influenza virus A/PR/8/34 from eight cDNA fragments. Virus Res 103 1-2 (2004) 155-161
5. He Q., Martinez-Sobrido L., Eko F.O., Palese P., Garcia-Sastre A., Lyn D., et al. Live-attenuated influenza viruses as delivery vectors for chlamydia vaccines. Immunology 122 1 (2007) 28-37
6. Stukova M.A., Sereinig S., Zabolotnyh N.V., Ferko B., Kittel C., Romanova J., et al. Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. Tuberculosis (Edinb) 86 3-4 (2006) 236-246
7. Sereinig S., Stukova M., Zabolotnyh N., Ferko B., Kittel C., Romanova J., et al. Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge. Clin Vaccine Immunol 13 8 (2006) 898-904
8. Kittel C., Ferko B., Kurz M., Voglauer R., Sereinig S., Romanova J., et al. Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment. J Virol 79 16 (2005) 10672-10677
9. Strobel I., Krumbholz M., Menke A., Hoffmann E., Dunbar P.R., Bender A., et al. Efficient expression of the tumor-associated antigen MAGE-3 in human dendritic cells, using an avian influenza virus vector. Hum Gene Ther 11 16 (2000) 2207-2218
10. Miyahira Y., Garcia-Sastre A., Rodriguez D., Rodriguez J.R., Murata K., Tsuji M., et al. Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. Proc Natl Acad Sci USA 95 7 (1998) 3954-3959
11. Nakaya Y., Zheng H., and Garcia-Sastre A. Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants. Vaccine 21 17-18 (2003) 2097-2106
12. Ferko B., Katinger D., Grassauer A., Egorov A., Romanova J., Niebler B., et al. Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract. J Infect Dis 178 5 (1998) 1359-1368
13. Gherardi M.M., Najera J.L., Perez-Jimenez E., Guerra S., Garcia-Sastre A., and Esteban M. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. J Virol 77 12 (2003) 7048-7057
14. Ferko B., Stasakova J., Sereinig S., Romanova J., Katinger D., Niebler B., et al. Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice. J Virol 75 19 (2001) 8899-8908
15. Gonzalo R.M., Rodriguez D., Garcia-Sastre A., Rodriguez J.R., Palese P., and Esteban M. Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. Vaccine 17 7-8 (1999) 887-892
16. Muster T., Ferko B., Klima A., Purtscher M., Trkola A., Schulz P., et al. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J Virol 69 11 (1995) 6678-6686
17. Muster T., Guinea R., Trkola A., Purtscher M., Klima A., Steindl F., et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 68 6 (1994) 4031-4034
18. Sexton A., De Rose R., Reece J.C., Alcantara S., Loh L., Moffat J.M., et al. Evaluation of recombinant influenza-SIV vaccines in macaques. J Virol 83 15 (2009) 7619-7628
19. Hoffmann E., Neumann G., Kawaoka Y., Hobom G., and Webster R.G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 97 11 (2000) 6108-6113
20. Van Baalen C.A., Kwa D., Verschuren E.J., Reedijk M.L., Boon A.C., De Mutsert G., et al. Fluorescent antigen-transfected target cell cytotoxic T lymphocyte assay for ex vivo detection of antigen-specific cell-mediated cytotoxicity. J Infect Dis 192 7 (2005) 1183-1190
21. Shinya K., Fujii Y., Ito H., Ito T., and Kawaoka Y. Characterization of a neuraminidase-deficient influenza a virus as a potential gene delivery vector and a live vaccine. J Virol 78 6 (2004) 3083-3088
22. Van Baalen C.A., Schutten M., Huisman R.C., Boers P.H., Gruters R.A., and Osterhaus A.D. Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro. J Virol 72 8 (1998) 6851-6857
23. Lee J.K., Stewart-Jones G., Dong T., Harlos K., Di Gleria K., Dorrell L., et al. T cell cross-reactivity and conformational changes during TCR engagement. J Exp Med 200 11 (2004) 1455-1466
24. Voeten J.T., Rimmelzwaan G.F., Nieuwkoop N.J., Lovgren-Bengtsson K., and Osterhaus A.D. Introduction of the haemagglutinin transmembrane region in the influenza virus matrix protein facilitates its incorporation into ISCOM and activation of specific CD8(+) cytotoxic T lymphocytes. Vaccine 19 4-5 (2000) 514-522
25. Palmer D.F., Dowdle W.R., Coleman M.T., and Schild G.C. Haemagglutination-inhibition test. Advanced laboratory techniques for influenza diagnosis: procedural guide (1975), US Dept. of Health and Welfare, Atlanta 25-62
26. Mishin V.P., Nedyalkova M.S., Hayden F.G., and Gubareva L.V. Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model. Vaccine 23 22 (2005) 2922-2927